Gilead

Oncology

Can CAR-T first movers keep pace in a rapidly evolving marke...

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.

Patients

Gilead's HIV success and controversy: Expanding access amid ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine.

Oncology

Ibrahim Elhoussieny and Warner Biddle at ASCO 2024

ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny

ASCO is always an interesting show for Kite, the Gilead Sciences subsidiary focused on cell therapy.

R&D

4 years on: Remembering the COVID-19 pandemic

This year, Monday 11th March marked four years since the World Health Organization (WHO) declared COVID-19 a global pandemic.

News

Gilead, Arcus say TIGIT combo encouraging in GI cancer

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy

Sales & Marketing

All eyes remain on US government patent dispute with Gilead

A high-stakes court battle is currently being fought in the US, with the government accusing a big pharma company of patent infringement for the first time.